key: cord-0837600-l47jyou4 authors: Robotti, Carlo; Costantini, Giovanni; Saggio, Giovanni; Cesarini, Valerio; Calastri, Anna; Maiorano, Eugenia; Piloni, Davide; Perrone, Tiziano; Sabatini, Umberto; Ferretti, Virginia Valeria; Cassaniti, Irene; Baldanti, Fausto; Gravina, Andrea; Sakib, Ahmed; Alessi, Elena; Pascucci, Matteo; Casali, Daniele; Zarezadeh, Zakarya; Zoppo, Vincenzo Del; Pisani, Antonio; Benazzo, Marco title: Machine learning-based voice assessment for the detection of positive and recovered COVID-19 patients date: 2021-11-26 journal: J Voice DOI: 10.1016/j.jvoice.2021.11.004 sha: 3a6797aaa60232496872565b6369d40459fe8a57 doc_id: 837600 cord_uid: l47jyou4 Many virological tests have been implemented during the COVID-19 pandemic for diagnostic purposes, but they appear unsuitable for screening purposes. Furthermore, current screening strategies are not accurate enough to effectively curb the spread of the disease. Therefore, the present study was conducted within a controlled clinical environment to determine eventual detectable variations in the voice of COVID-19 patients, recovered and healthy subjects, and also to determine whether machine learning-based voice assessment (MLVA) can accurately discriminate between them, thus potentially serving as a more effective mass-screening tool. Three different subpopulations were consecutively recruited: positive COVID-19 patients, recovered COVID-19 patients and healthy individuals as controls. Positive patients were recruited within 10 days from nasal swab positivity. Recovery from COVID-19 was established clinically, virologically and radiologically. Healthy individuals reported no COVID-19 symptoms and yielded negative results at serological testing. All study participants provided three trials for multiple vocal tasks (sustained vowel phonation, speech, cough). All recordings were initially divided into three different binary classifications with a feature selection, ranking and cross-validated RBF-SVM pipeline. This brough a mean accuracy of 90.24%, a mean sensitivity of 91.15%, a mean specificity of 89.13% and a mean AUC of 0.94 across all tasks and all comparisons, and outlined the sustained vowel as the most effective vocal task for COVID discrimination. Moreover, a 3-way classification was carried out on an external test set comprised of 30 subjects, 10 per class, with a mean accuracy of 80% and an accuracy of 100% for the detection of positive subjects. Within this assessment, recovered individuals proved to be the most difficult class to identify, and all the misclassified subjects were declared positive; this might be related to mid and short-term vocal traces of COVID-19, even after the clinical resolution of the infection. In conclusion, MLVA may accurately discriminate between positive COVID-19 patients, recovered COVID-19 patients and healthy individuals. Further studies should test MLVA among larger populations and asymptomatic positive COVID-19 patients to validate this novel screening technology and test its potential application as a potentially more effective surveillance strategy for COVID-19. The Coronavirus Disease 2019 pandemic, caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), has reached more than 200 countries to date, jeopardizing healthcare systems and national administrations worldwide [1] [2] [3] . At the time of writing (September 2021), over 225 million confirmed cases and more than 4.5 million deaths had been reported globally [4] . To curb the alarming spread of the disease, several virological tests were promptly implemented, including reverse transcription-polymerase chain reaction (RT-PCR) for viral RNA detection [5] , serologic testing for immunoglobulins M (IgM) and G (IgG) quantification [6] and rapid diagnostic kits [7, 8] . Nevertheless, available testing strategies suffer from critical limitations in accuracy and most appropriate clinical applications [9, 10] . Furthermore, inadequate testing infrastructures, high costs, lack of testing components, and long waiting times for results might have contributed to the poor control of the pandemic [11, 12] , leading to an underestimation of the infection's actual burden [13] . Specifically, the limitations of current screening strategies (symptoms checklists, temperature checking) [14, 15] stress the need for new instruments, which should be highly sensitive, but also widely accessible, non-invasive, cost-effective, and able to provide results quickly and at scale [16] . Within this frame, the present research project was designed to test a novel COVID-19 screening tool based on voice analysis through machine learning (ML). Conventional voice analysis proved useful in detecting distinguishing acoustic features of pathologies impairing all structures and systems responsible for phonation, including lungs [17] [18] [19] , trachea [20] , larynx [21] [22] [23] , vocal folds [24, 25] and central nervous system [26] [27] [28] [29] [30] . Furthermore, encouraging results had been obtained for disorders impairing voice production mechanisms only secondarily, including cardiovascular diseases [31] [32] [33] [34] and diabetes [35] . Advantageously, ML-based voice assessment (MLVA) allows processing thousands of acoustic variables simultaneously, benefiting from the computational power of properly trained algorithms [36, 37] . Moreover, MLVA confirmed its efficacy even on samples gathered through non-professional recording instruments (i.e., smartphones) [38, 39] , making this technology potentially available on a global scale through mobile devices. images or Long Short Term Memory networks (LSTM), is commonly considered as the huge alternative to "traditional" machine learning pipeline methods. The advantages include the fact that it allows for the extraction of very complex features, through the repeated non-linear transformation of the data, and that it's completely data-driven, without the requirement of a suitable pre-processing of the training set. However, deep learning is often hard to use for small datasets, requiring larger sets (often in the order of thousands and more [40] ) by its nature and/or a suitable data augmentation procedure, which indeed becomes a preprocessing artifact. Moreover, DL models usually comprehend a large number of parameters and require more hardware resources for their training. Several studies [41] [42] eloquently demonstrate the possibilities of DL for pathological speech assessment, yet the datasets and the accuracy values are often comparable with traditional ML methods for the same pathologies, namely Parkinson's disease [43] or dysphonia [44] . Moreover, a study by Hasan et al. [45] compares CNN and SVM for hyper-spectral image recognition with the results being very similar, with a slight edge of the SVM. Although apparently different from our task, hyper-spectral images are in fact translated as image inputs for CNN's and as a set of complex features for the SVM, which is exactly how a speech-based pathology detection is carried out. We considered the two approaches equally promising, and hugely problem-dependent. For this specific study, we chose a traditional SVM-based machine learning pipeline based on many state-of-the-art performances on pathology identification with small datasets, but also considering our need to still retain clinically relevant features in our analysis, which would be a much more difficult task using a high-abstraction DL-based approach. Interestingly, over the last few months, some research groups have been racing worldwide to search for COVID-19 acoustic biomarkers [46] , mainly focusing on cough and breath sounds and yielding promising results [47] [48] [49] . The DiCOVA challenge within the Interspeech 2021 conference is also worth mentioning, where several teams tested algorithms for the identification of COVID-19 from crowdsourced voice samples [50] , with the winning team accuracy being 87%. Nonetheless, several limitations of these studies appear noteworthy. Firstly, data was mainly collected through web-based platforms, thus bounding researchers to rely on patients' selfdeclarations. Secondly, being conducted outside of controlled clinical settings, incomplete clinical data were often provided (i.e., testing type and timing, inclusion and exclusion criteria, COVID-19 symptoms). Thirdly, to the best of our knowledge, only two studies included vocal samples other than cough in the analyses [50, 51] . Specifically, in our opinion, proper speech tasks could provide valuable additional features for MLVA implementation, in reason of the complex interactions between voice-production subsystems [36, 52] and their peculiar impairments in COVID-19 [53] [54] [55] 57] . Lastly, no ML study enrolled recovered COVID-19 patients to date, even though they may represent a crucial population for multiple reasons, including potential residual viral spreading [58] [59] [60] and severe long-term disabilities [61] [62] [63] . Therefore, the present study was designed to test MLVA as a potential screening tool for COVID-19 within a controlled clinical setting, collecting multiple vocal tasks (sustained phonation, speech, cough) with commercially available smartphones from three different subpopulations (positive COVID patients, recovered negative COVID-19 patients, healthy controls). The study was conducted between March 2020 and October 2020 at three Italian COVID-19 units after approval of the ethics committees (IRCCS San Matteo Foundation, Pavia, Italy, reference number 20200053388; Ospedale dei Castelli, Ariccia, Italy, reference number 0064181/2020; Policlinico Tor Vergata Foundation, Rome, Italy, reference number 0012909/2020). The study was conducted following the principles stated by the Helsinki Declaration [64] . Ultrasound (LUS) score ≤ 3 were recruited, to exclude subjects with residual pulmonary fibrosis [65] [66] [67] . Healthy individuals were recruited among hospital staff members and their acquaintances if they never had tested positive for COVID-19, reported no COVID-19 symptoms, nor had unprotected exposure to COVID-19 cases (known or suspected). Serum samples (SS) for antibodies quantification were collected from healthy participants at least 20 days after recording sessions [68] [69] [70] , yielding negative results. Written informed consent was obtained from all participants. All data was pseudonymized. Recording sessions were conducted in similar hospital rooms, with quiet environments and tolerable levels of background noise. Specifically, no machines producing static or impulsive noises were running in the background and no other voices were captured while recording. Moreover, global quality of the recordings was assessed by ear by three independent audio engineers, rating samples as "acceptable" based on voice clarity, absence of noticeable reverb, absence of noticeable hiss or hum noises, and intelligible phonation. Voice samples were recorded with Huawei Y6-2019 smartphones (Huawei Technologies Co., Ltd., Shenzhen, China), in high quality and uncompressed format (.wav, 16-bit, 44.1 kHz). Devices were carefully disinfected after each use, according to the manufacturer's instructions. Participants were instructed to sit up straight on chairs with no armrests, keeping elbows and arms relaxed to avoid arm and shoulder strain. During recording sessions, all participants removed their masks not to alter acoustic signals nor speech intelligibility [71] [72] [73] . The device's microphone was placed 15-20 cm in front of the participants' mouths. Three distinct vocal-tasks were performed by each participant: (1) sustained voicing of the vowel /a/ (like in "bra"), at comfortable pitch and loudness, for at least 5 seconds; (2) a common Italian saying ("a caval donato non si guarda in bocca", literally "do not look a gift horse in the mouth"); (3) cough. Three trials were recorded for each task. For the vowel and the sentence tasks, the trial with the lowest competing noise was then selected for MLVA [74] , while all three cough trials were considered for the analyses. Recordings with poor audio quality or mispronunciation errors were then discarded from the analyses (Table S1 in the Supplement). All recordings were uploaded to a secure institutional server. Audio files were then trimmed to retain only vocalizing sections. Each participant provided three trials for each task effortlessly. Specifically, recording sessions required no more than two minutes for each participant. MLVA was performed in five steps: pre-processing, feature extraction (FE), feature selection (FS), feature ranking (FR), and classification (CL). First, raw audio data of all vocal tasks underwent preprocessing elaboration. Specifically, Root Mean Square (RMS) normalization was applied to feed the algorithms with normalized data, thus mitigating variations related to different recording environments. Subsequently, FE was performed embedding OpenSMILE (OpenSMILE; audEERING GmbH, Munich, Germany) [75] in a bash script, following previously validated protocols [39] . A total of 6373 unidimensional features was extracted using the configuration file of the INTERSPEECH2016 Computational Paralinguistics Challenge (IS ComParE 2016) feature dataset [75] . Subsequently, FS, FR and CL were performed using the software Weka (Waikato Environment for Knowledge Analysis; University of Waikato, Waikato, New Zealand) [76] . Starting from FS, audio files were organized into nine different datasets, with three binary comparisons between the classes, each being based on the three vocal tasks. Thus, the training set was arranged for one-versus-one comparisons, namely P versus H, P versus R and R versus H. According to a Greedy-Stepwise search method, each binary dataset underwent FS with a Correlation-Based approach [77] , retaining approximately 2% of the previously extracted features. FR was performed basing on heuristic merit factors through a linear SVM classifier [78] . The first fifty top-ranking features were preserved for each dataset, retaining the most informative content while maintaining a standardized number of features. Finally, CL was conducted through the SVM classifier (Radial Basis SVM), which was selected for its effectiveness within the analysis of relatively small datasets [79, 80] . Accuracy on the training set, for each binary classifier (binary MLVA), was calculated by means of a 10-fold cross-validation, dividing the whole set into folds and using a different one of those as a validation set each time. Final accuracy is the average of the ten accuracies obtained on each 9-to-1 set. On the other hand, the test accuracy on the external set was obtained by running the pre-trained binary models on the test data, unified with a majority voting system. Since each binary model is comprised of three subclassifiers, one per vocal task, a majority voting system was also used to unify the outputs of the three sub-classifiers. Those subjects who received three different responses from the three binary classifiers were deemed as "uncertain". Sensitivity and specificity were obtained through confusion matrices, as well as their three-class equivalent (H Accuracy, P Accuracy, R Accuracy). To compare clinical and demographic characteristics, statistical tests were performed using Stata (StataCorp 2019, Stata Statistical Software: Release 16, College Station, TX). Qualitative variables were summarized as absolute counts and percentages of each category, while quantitative variables were summarized as medians and interquartile ranges (IQRs). Fisher's exact test was used to compare categorical variables between the groups of patients. Mann-Whitney test and Kruskal-Wallis test (with Dunn's test for post-hoc comparisons) were used to compare quantitative variables between two or more groups of patients, respectively. Bonferroni's correction was applied to allow for multiple comparisons. Two-sided p-values were considered statistically significant when lower than 0.05. Seventy positive COVID-19 patients (group P) were consecutively enrolled at the COVID-19 Units of the enrolled institutions. To match this population, seventy participants were consecutively recruited among recovered negative COVID-19 patients and healthy individuals. These subjects make up the training set for the binary MLVA. Clinical and demographic data are reported in Table 2 . Moreover, thirty subjects (ten per class) have subsequently been collected for an external test sample which allowed MLVA to act as a three-way classifier. COVID-19 symptoms were reported by 77% of both positive and recovered patients (p > 0.90). More than 40% of symptomatic participants of both groups reported dyspnea on exertion and asthenia (p > 0.05). Cough, dyspnea at rest, blocked nose, and fever were reported more frequently by positive COVID-19 patients (p < 0.02 in all comparisons). Contrariwise, muscle pain was reported at a higher rate by recovered subjects as a residual symptom (p = 0.006). Finally, no relevant differences were highlighted for the remaining screened symptoms (p > 0.05). At the time of enrollment, COVID-19-related pneumonia had been diagnosed clinically and radiologically in 57% of positive patients; former diagnoses of COVID-19-related pneumonia were recorded instead for 96% of recovered patients (p < 0.001). Receiver Operating Characteristic (ROC) curves describing MLVA performances for each binary comparison between groups are depicted in Figure 1 and in Figures S1 and S2 in the Supplement [81] . Table 3 Table 4 . The final confusion matrix for all the test subjects is reported in Table 5 , while the compact 3x4 matrix is reported in Table 6 . The present investigation, conducted within a controlled clinical setting, demonstrated that MLVA can accurately discriminate between positive COVID-19 patients, recovered negative COVID-19 patients, and healthy individuals, by detecting highly-distinguishing patterns of audio features for all tasks across all study groups. In comparison to most previous works, this study expands MLVA analyses to proper speech tasks, providing further evidence in support of the potential clinical application of this novel screening tool for COVID-19. Binary MLVA (cross-validated on the training set) yielded promising results for all tasks and all comparisons between groups, with a satisfactory mean accuracy of 90.24% and a significantly high mean AUC of 0.94 [82] . Previous studies testing cough and breath sounds reported encouraging results in terms of accuracy (range 88.89%-98.50%) and AUC (range 0.80-0.98) [48, 49] . However, comparisons with literature appear scarcely feasible, primarily for methodological reasons. Firstly, previous studies searching for COVID-19 acoustic biomarkers relied almost exclusively on cough, since it represents a well-renowned COVID-19 core symptom [83] [84] [85] . Pre-COVID-19 ML studies demonstrated the relevance of cough samples for detecting multiple respiratory conditions [86, 87] . However, it is conceivable that proper speech tasks may provide additional valuable features for MLVA, potentially even more representative of the multifaceted interactions between phonatory subsystems [36, 52] and their impairment in COVID-19 [53] [54] [55] 57] . Indeed, the vowel task proved higher accuracy and AUC values than cough when discriminating between groups P and H and between groups P and R, demonstrating lower performances only when discriminating between groups R and H, thus confirming that speech tasks may have at least similar informative contents. Foreseeing the need for an automatic tool, a three-way classifier was also developed by unifying the three models with a majority voting system. Thus, the features used for the classifications were the same used for the binary MLVA. This classification yielded 80% accuracy for the identification of subjects of group H, a 100% accuracy for subjects of group P and a 60% accuracy for subjects of group R, with 10% classified as "uncertain". With a mean of 80%, the classifier still yields relevant accuracy, comparable to that of conventional nasal swabs, with the additional advantage of preliminarily discriminating recovered subjects. Furthermore, the trend of the vowel being the best discriminating task, shortly followed by the sentence, was confirmed. It is worth noting that all misclassified recovered subjects were The present research was conceived to overcome the critical issues of current screening strategies, such as symptoms checklists and temperature checking. Regarding symptoms checklists, a recent review concluded that commonly screened COVID-19 signs and symptoms have low diagnostic accuracy, since neither presence nor absence of symptoms is accurate enough to confirm or rule out the disease [14] . Temperature screening appears to be an unreliable, high-cost, and low-yield strategy [15] . Indeed, in a study investigating European patients' clinical features, only 45% of mild-to-moderate COVID-19 patients had fever, and the rate dropped to 9% when asymptomatic individuals were also considered [84] . Therefore, based on our preliminary results, we believe that MLVA could represent a more reliable, cost-effective, non-invasive, and widely deployable testing where virological tests are scarcely accessible or poorly available [90] . Furthermore, MLVA could also be employed at scale to preselect candidates for virological testing because of its high sensitivity and specificity. Interestingly, a recent meta-analysis highlighted that sensitivity and specificity of currently available COVID-19 diagnostics are not equally high, ranging from 97.2% of RT-PCR analyses of sputum samples to 73.3% and even 62.3% when RT-PCR is performed on NS specimens and saliva, respectively [91] . This variability may be primarily related to COVID-19 clinical course, since chances of viral detection on biological samples depend on specific collection times [91, 92] . Moreover, being time-consuming and expensive [93] , these technologies appear unsuitable for reiterated population screening. Contrariwise, effective surveillance regimens (aimed at rapidly filtering infected individuals out from the population, thus preventing further spreading) should focus instead on high-frequency testing, even with lower analytic sensitivity [94] . Both high-sensitivity and low-sensitivity tests can detect the infection within its narrow transmission window, but only frequently repeated tests can spot it during its very early phases [95] . In this matter, being a low-cost and widely spreadable technology (i.e., Although the test set is not large, preliminary results stresses the potential utility of MLVA as an on-site screening tool used in substitution or in addition to nasal swabs for pre-diagnosis, as well as the possibility to develop an application for real-time, remote self-assessment. In these regards, we consider MLVA to only be a preliminary tool which should suggest a more extensive examination in case of a positive outcome. Recruited healthy individuals had to respect strict inclusion criteria. Furthermore, SS testing was conducted at least twenty days after recording sessions, yielding negative results. Similarly, Laguarta [49] crowdsourced cough samples from healthy individuals who declared having tested negative, nevertheless not specifying testing type. For the present investigation, control subjects did not undergo baseline NS testing, since NS may yield falsely-negative results [98] , especially in early phases of COVID-19 and with potentially high rates [99] . Instead, numerous studies demonstrated that seroconversion rates in positive COVID-19 patients reach almost 100% 15 to 19 days after symptoms onset [68] [69] [70] , suggesting that delayed immunological confirmation might offer a more reliable strategy when recruiting healthy control subjects during the present pandemic. Noteworthily, this is the first study testing MLVA on recovered COVID-19 patients, with promising results. Specifically, the satisfactory classification accuracy obtained discriminating between positive and recovered patients suggests that MLVA may detect different COVID-19 clinical phases. Therefore, further studies should test MLVA in monitoring disease progression. Moreover, the results obtained within the discrimination between recovered and healthy individuals suggest that COVID-19 may leave detectable vocal traces even without clinically evident pulmonary impairments. In fact, all recovered patients had a Lung Ultrasound Score of 3 or lower [65] [66] [67] . The importance of recruiting recovered patients lies in the fact that these subjects might test positive again, although the reasons behind it (i.e., reinfections, new viral variants, reactivation of former infections) and eventual residual viral spreading are still debated [58] [59] [60] . Ultimately, it is expected that healthcare systems will face critical challenges in the future for the management of recovered COVID-19 patients due to potential long-term invalidating sequelae [61] [62] [63] 100, 101] . In this matter, MLVA could offer a feasible and low-cost strategy to detect these subjects among the general population. recovered COVID-19 patients (77%) presented clinical symptoms of the disease. Future studies should address this experimental approach to positive but asymptomatic patients, thus improving MLVA performances in the pre-clinical phases of COVID-19 [102] . Secondly, we are aware that our study's sample size was limited, and that the lack of sample size calculation limits the ability to draw ultimate inferences in support of a prompt employment of MLVA in clinical practice. Therefore, although promising, the results of the present study should be intended as preliminary [103] . However, the adopted rigorous methodology and the homogenous population of this study (same ethnicity, language and nationality) support the quality of our results, hopefully dispelling some skepticism towards this pioneering screening technology. Wider multicultural and multilanguage study should be designed to confirm our findings among international populations, in order to rapidly answer the pressing need for a more effective surveillance strategy for COVID-19 [104] . In Table S2 . Covid-19: how doctors and healthcare systems are tackling coronavirus worldwide Covid-19 -Implications for the Health Care System The early impact of the Covid-19 pandemic on the global and Turkish economy World Health Organization (WHO) Coronavirus (COVID19) Dashboard Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR Antibody testing for coronavirus disease 2019: not ready for prime time Diagnostic accuracy of serological tests for covid-19: systematic review and meta-analysis Fast coronavirus tests: what they can and can't do Molecular diagnostic technologies for COVID-19: Limitations and challenges Effectiveness of tests to detect the presence of SARS-CoV-2 virus, and antibodies to SARS-CoV-2, to inform COVID-19 diagnosis: a rapid systematic review COVID-19 Testing Failure COVID-19 as the Leading Cause of Death in the United States Substantial underestimation of SARS-CoV-2 infection in the United States Signs and symptoms to determine if a patient presenting in primary care or hospital outpatient settings has COVID-19 disease Return to work during coronavirus disease 2019 (COVID-19): Temperature screening is no panacea Assessing the value of screening tools: reviewing the challenges and opportunities of cost-effectiveness analysis Effect of lung volume on voice onset time (VOT) Tuberculosis Screening by Means of Speech Analysis Voice-based screening and monitoring of chronic respiratory conditions Breath sounds, asthma, and the mobile phone Towards a computer tool for automatic detection of laryngeal cancer Acoustic Analysis of Chronic Laryngitis Voice analysis in adductor spasmodic dysphonia: Objective diagnosis and response to botulinum toxin Short-term cepstral analysis applied to vocal fold edema detection Cepstral analysis of voice in persons with vocal nodules Voice analysis as an objective state marker in bipolar disorder A Prototype for the Voice Analysis Diagnosis of Alzheimer's Disease Selection of voice parameters for Parkinson's disease prediction from collected mobile data Novel speech signal processing algorithms for high-accuracy classification of Parkinson's disease Linguistic Features Identify Alzheimer's Disease in Narrative Speech Interactions between voice fundamental frequency and cardiovascular parameters. Preliminary results and physiological mechanisms Coronary heart disease detection from voice analysis Voice Signal Characteristics Are Independently Associated With Coronary Artery Disease Non-invasive vocal biomarker is associated with pulmonary hypertension Voice based detection of type 2 diabetes mellitus Are Sensors and Data Processing Paving the Way to Completely Non-invasive and Not-painful Medical Tests for Widespread Screening and Diagnosis Purposes? Worldwide Healthy Adult Voice Baseline Parameters: A Comprehensive Review Exploring the feasibility of smart phone microphone for measurement of acoustic voice parameters and voice pathology screening Machine-Learning Analysis of Voice Samples Recorded through Smartphones: The Combined Effect of Ageing and Gender Learning Deep Face Representations Using Small Data Deep Learning Solution for Pathological Voice Detection using LSTM-based Autoencoder Hybrid with Multi-Task Learning Machine Learning Approaches for Detection and Diagnosis of Parkinson's Disease -A Review Voiceprints analysis using MFCC and SVM for detecting patients with Parkinson's disease Voice Cepstral Analysis in Adductor-Type Spasmodic Dysphonia A Comparison Between Support Vector Machine (SVM) and Convolutional Neural Network (CNN) Models For Hyperspectral Image Classification Alexa, do I have COVID-19? AI4COVID-19: AI enabled preliminary diagnosis for COVID-19 from cough samples via an app Exploring Automatic Diagnosis of COVID-19 from Crowdsourced Respiratory Sound Data COVID-19 Artificial Intelligence Diagnosis Using Only Cough Recordings DiCOVA Challenge: Dataset, task, and baseline system for COVID-19 diagnosis using acoustics. Interspeech 2021 challenge SARS-CoV-2 Detection From Voice Artificial intelligence enabled preliminary diagnosis for COVID-19 from voice cues and questionnaires Mechanics of human voice production and control Isolated bulbar palsy after SARS-CoV-2 infection Novel Coronavirus (COVID-19) Pneumonia in Two Patients With Lung Cancer Performance of Radiologists in Differentiating COVID-19 from Non-COVID-19 Viral Pneumonia at Chest CT Neurobiology of COVID-19 Positive RT-PCR Test Results in Patients Recovered From COVID-19 Retest positive for SARS-CoV-2 RNA of "recovered" patients with COVID-19: Persistence, sampling issues, or re-infection? What we know about covid-19 reinfection so far Outcomes of Cardiovascular Magnetic Resonance Imaging in Patients Recently Recovered From Coronavirus Disease 2019 (COVID-19) Follow-up studies in COVID-19 recovered patients -is it mandatory? Laryngeal complications of COVID-19 World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects Is There a Role for Lung Ultrasound During the COVID-19 Pandemic? Proposal for International Standardization of the Use of Lung Ultrasound for Patients With COVID-19: A Simple, Quantitative, Reproducible Method A New Lung Ultrasound Protocol Able to Predict Worsening in Patients Affected by Severe Acute Respiratory Syndrome Coronavirus 2 Antibody responses to SARS-CoV-2 in patients with COVID-19 Antibody Responses to SARS-CoV-2 in Patients With Novel Coronavirus Disease Longitudinal Monitoring of SARS-CoV-2 IgM and Effects of face masks on acoustic analysis and speech perception: Implications for peri-pandemic protocols Impact of face masks on voice radiation Short report on the effects of SARS-CoV-2 face protective equipment on verbal communication Speech production modifications produced by competing talkers, babble, and stationary noise The INTERSPEECH 2016 Computational Paralinguistics Challenge: Deception, Sincerity and Native Language. 16 th Annual Conference of the International Speech Communication Association The Data Mining and Knowledge Discovery Handbook Theory of Psychological Measurement Gene Selection for Cancer Classification using Support Vector Machines SVM-Based Audio Classification for Content-Based Multimedia Retrieval SVM based transcription system with short-term memory oriented to polyphonic piano music An introduction to ROC analysis Measuring the accuracy of diagnostic systems Olfactory and gustatory dysfunctions as a clinical presentation of mild-to-moderate forms of the coronavirus disease (COVID-19): a multicenter European study Clinical and epidemiological characteristics of 1420 European patients with mild-to-moderate coronavirus disease 2019 Blood ozonization in patients with mild to moderate COVID-19 pneumonia: a single centre experience A prospective multicentre study testing the diagnostic accuracy of an automated cough sound centred analytic system for the identification of common respiratory disorders in children FluSense: A Contactless Syndromic Surveillance Platform for Influenza-Like Illness in Hospital Waiting Areas RASTA processing of speech. Speech and Audio Processing COVID-19 After Effects: Concerns for Singers Access to lifesaving medical resources for African countries: COVID-19 testing and response, ethics, and politics Systematic review with meta-analysis of the accuracy of diagnostic tests for COVID-19 SARS-CoV-2 viral load in upper respiratory specimens of infected patients The incubation period of coronavirus disease 2019 (COVID-19) from publicly reported confirmed cases: estimation and application Rethinking Covid-19 Test Sensitivity -A Strategy for Containment False Negative Tests for SARS-CoV-2 Infection -Challenges and Implications Reflection on modern methods: Revisiting the area under the ROC Curve Sensitivity, specificity, receiver-operating characteristic (ROC) curves and likelihood ratios: communicating the performance of diagnostic tests False-negative results of initial RT-PCR assays for COVID-19: A systematic review Recurrence of COVID-19 after recovery: a case report from Italy The "post-COVID" syndrome: How deep is the damage? Postdischarge symptoms and rehabilitation needs in survivors of COVID-19 infection: A cross-sectional evaluation Asymptomatic SARS Coronavirus 2 infection: Invisible yet invincible Is my cough COVID-19? Challenges and Opportunities in Deploying COVID-19 Cough AI Systems The authors would like to thank all patients and all healthy volunteers for kindly supporting the present research project. The authors would also like to dedicate this paper to all Italian healthcare professionals strenuously fighting against COVID-19.